Post Test
STEMI patients have higher mortality rates than found in random trials 20-30% variability in hospital care following ACC/AHA guidelines Invasive cardiac procedures have not been accepted as part of the ACC/AHA guidelines Excessive antithrombotic dosing reduces likelihood of bleeding
True False
Options include COX II selective and traditional NSAIDs Alternative treament choices follow the evaluation of risk factors for gastrointestinal complications, renal toxicity, and cardiovascular toxicity Alternatives to oral therapy would include interarticular therapy with hyaluronic acid or glucocorticoids Acetaminophen is the last line of pharmacologic intervention
Fondaparinux and enoxaparin Rivaroxaban and apixaban Eptifibatide and apixaban Rivaroxaban and enoxaparin
No evidence of drug-induced renal harm compared to placebo Serial infusions of nesiritide do not result in a demonstrable clinical benefit over intensive outpatient management of patients with CDHF Adherence to guideline-based therapy and meticulous follow-up care should be optimized for patients with CDHF All of the above
Natriuretic peptides Inotropes Initially, loop diuretics Nesiritide
>2 mg/dL >30 mL/min ≤50 mL/min ≤5 mg/dL
